Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

Suzanne Leijen, Sjaak A Burgers, Paul Baas, Dick Pluim, Matthijs Tibben, Erik van Werkhoven, Enzo Alessio, Gianni Sava, Jos H Beijnen, Jan H M Schellens

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science